Regulation of Langerhans Cell Migration by Invariant Gamma Delta T Cells

恒定 Gamma Delta T 细胞对朗格汉斯细胞迁移的调节

基本信息

  • 批准号:
    9136642
  • 负责人:
  • 金额:
    $ 15.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-27 至 2017-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dermatitis is a common manifestation of lupus that can cause scarring and disfigurement. Lupus dermatitis is often difficult to treat and relatively little is known about its pathogenesis. The outer layer of the skin, the epidermis, contains two immune cells, the Langerhans cell (LC) and dendritic epidermal T cells (DETC). The relative simplicity of the skin makes it an ideal model for studying organ level immune tolerance. Recent studies have pointed to Langerhans cells as important regulators of skin tolerance. Our lab has recently shown that LC migration is impaired in mice prone to lupus dermatitis. DETCs are known to help promote wound healing but their overall function remains unclear. Exciting new data from our lab have shown a hereto- unknown function for the DETCs, that they regulate LC migration. Treatment with alpha-galactosylceramide (GalCer) improves dermatitis, increases DETC numbers in the epidermis, and restores LC migration in lupus prone mice. In this grant, we hypothesize that DETCs regulate the migration of LCs, and that LC-DETC interaction in the skin serves as a regulatory network that protects against skin inflammation. To test this hypothesis, we will: determine the role of DETC in LC migration, and investigate the mechanism or mechanisms by which DETCs regulate LC migration (Aim 1). In Aim 2, we will investigate the factors responsible for the LC migration defect seen in MRL mice. Guided by our preliminary findings that MRL-lpr mice also have a marked reduction in DETC numbers and that DETC-LC appear to interact with each other in vivo and in vitro, we hypothesize that impaired LC migration in lupus mice is due to reduced numbers of DETC in skin; increasing DETC numbers will enhance LC migration, and reduce skin inflammation. Future studies will start to transition our studies of DETCs and LC migration to human samples. Better understanding of the factors regulating LC migration may lead to novel therapies for the control of lupus dermatitis.
描述(由申请人提供):皮炎是狼疮的常见表现,可导致疤痕和毁容。狼疮性皮炎通常很难治疗,其发病机制知之甚少。皮肤的外层(表皮)含有两种免疫细胞:朗格汉斯细胞(LC)和树突状表皮T细胞(DETC)。皮肤的相对简单性使其成为研究器官水平免疫耐受性的理想模型。最近的研究指出朗格汉斯细胞是皮肤耐受性的重要调节因子。我们的实验室最近表明,LC迁移受损的小鼠容易狼疮皮炎。已知DETC有助于促进伤口愈合,但其总体功能仍不清楚。来自我们实验室的令人兴奋的新数据已经显示了DETC的未知功能,即它们调节LC迁移。α-半乳糖神经酰胺(GalCer)治疗可改善皮炎,增加表皮中的DETC数量,并恢复狼疮易感小鼠的LC迁移。在这项研究中,我们假设DETC调节LC的迁移,皮肤中的LC-DETC相互作用作为一个调节网络,保护皮肤免受炎症。为了验证这一假设,我们将:确定DETC在LC迁移中的作用,并研究DETC调节LC迁移的机制(目的1)。在目标2中,我们将研究MRL小鼠中观察到的LC迁移缺陷的相关因素。根据我们的初步发现,MRL-lpr小鼠的DETC数量也显著减少,并且DETC-LC似乎在体内和体外相互作用,我们假设狼疮小鼠中LC迁移受损是由于皮肤中DETC数量减少;增加DETC数量将增强LC迁移,并减少皮肤炎症。未来的研究将开始将我们对DETC和LC迁移的研究转移到人体样本中。更好地了解调节LC迁移的因素可能会导致控制狼疮性皮炎的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER Junghan KIM其他文献

PETER Junghan KIM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER Junghan KIM', 18)}}的其他基金

Regulation of Langerhans Cell Migration by Invariant Gamma Delta T Cells
恒定 Gamma Delta T 细胞对朗格汉斯细胞迁移的调节
  • 批准号:
    8551372
  • 财政年份:
    2012
  • 资助金额:
    $ 15.27万
  • 项目类别:
Regulation of Langerhans Cell Migration by Invariant Gamma Delta T Cells
恒定 Gamma Delta T 细胞对朗格汉斯细胞迁移的调节
  • 批准号:
    8731071
  • 财政年份:
    2012
  • 资助金额:
    $ 15.27万
  • 项目类别:
Regulation of Langerhans Cell Migration by Invariant Gamma Delta T Cells
恒定 Gamma Delta T 细胞对朗格汉斯细胞迁移的调节
  • 批准号:
    8281115
  • 财政年份:
    2012
  • 资助金额:
    $ 15.27万
  • 项目类别:
Regulation of Langerhans Cell Migration by Invariant Gamma Delta T Cells
恒定 Gamma Delta T 细胞对朗格汉斯细胞迁移的调节
  • 批准号:
    8930439
  • 财政年份:
    2012
  • 资助金额:
    $ 15.27万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Operating Grants
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
  • 批准号:
    23K14742
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
  • 批准号:
    10864719
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
  • 批准号:
    10586562
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
  • 批准号:
    23K06589
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
  • 批准号:
    10623380
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
  • 批准号:
    10735148
  • 财政年份:
    2023
  • 资助金额:
    $ 15.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了